{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:11Z","timestamp":1777859591456,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Evidence supports the safe administration of levetiracetam as a rapid intravenous push (IVP) in patients experiencing breakthrough seizures or status epilepticus. Use of this route of administration may decrease morbidity and mortality by reducing time to medication delivery. Though this practice has become increasingly common in adults, the safety of IVP levetiracetam in pediatric patients is not well documented.\n                    <jats:bold>Objective:<\/jats:bold>\n                    To evaluate the safety of IVP levetiracetam in pediatric patients.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Patients who received IV piggyback (IVPB) or IVP levetiracetam and were between the ages of 12\u00a0months and 18\u00a0years old were eligible for inclusion. Medication regimen data recorded includes the dose of levetiracetam, number of doses administered, and total days of administration. Additionally, time points related to order entry, pharmacist verification, and dose administration was recorded. Safety endpoints included rates of bradycardia, hypotension, behavioral changes, and cutaneous drug reactions. Descriptive and inferential statistical analysis was performed using SPSS software.\n                    <jats:bold>Results:<\/jats:bold>\n                    This study showed IVP levetiracetam has a similar rate of adverse effects when compared to IVPB levetiracetam in patients over the age of one (5.5% vs 7.5%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.3589). In addition, there was improvement in the time to administration of levetiracetam (50\u00a0min in the IVPB group and 23\u00a0min in the IVP group [\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .0008]).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Pediatric patients who received undiluted (100\u00a0mg\/mL) levetiracetam IVP over 5\u00a0min had a similar adverse event incidence when compared to those who received the anti-epileptic drug (AED) as an IVPB. This evaluation demonstrated that doses up to 1500\u00a0mg of undiluted IVP levetiracetam is safe for pediatric patients.\n                  <\/jats:p>","DOI":"10.1177\/08971900251355333","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T02:36:18Z","timestamp":1750991778000},"page":"104-108","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of Intravenous Push Levetiracetam in an Academic Children\u2019s Hospital"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-495X","authenticated-orcid":false,"given":"Aneesha","family":"Santhosh","sequence":"first","affiliation":[{"name":"Rutgers University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Abazia","sequence":"additional","affiliation":[{"name":"Rutgers University"},{"name":"Robert Wood Johnson University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Lise","sequence":"additional","affiliation":[{"name":"Robert Wood Johnson University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Awad","sequence":"additional","affiliation":[{"name":"Robert Wood Johnson University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"Data Resource Center for Child and Adolescent Health. National Survey of children's health 2022: prevalence of current epilepsy or seizure disorder nationwide [Internet]. Available from: https:\/\/www.childhealthdata.org\/browse\/survey\/results?q=10071&r=1. Accessed March 5 2025."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5040047"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-16.1.48"},{"key":"e_1_3_6_5_2","unstructured":"European Medicines Agency: Keppra-H-C-277-X-0046: EPAR-scientific discussion of the European medicine agency 2006. Accessed January 4 2022."},{"key":"e_1_3_6_6_2","volume-title":"Package insert. Levetiracetam","year":"2009","unstructured":"Package insert. Levetiracetam. Brussels, Belgium: UCB; 2009."},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01122-7"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30722-6"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30724-X"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-021-01237-w"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.S2.555"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000901"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.166558"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900231176457"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2898"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/08830738241255992"},{"key":"e_1_3_6_19_2","volume-title":"General Chapter <797> Pharmaceutical Compounding\u2014Sterile Preparations. USP43-NF38","author":"United States Pharmacopeial Convention","year":"2019","unstructured":"United States Pharmacopeial Convention. General Chapter <797> Pharmaceutical Compounding\u2014Sterile Preparations. USP43-NF38. Rockville, MD: U.S. Pharmacopeial Convention; 2019."},{"key":"e_1_3_6_20_2","unstructured":"USP <797> FAQs. United states pharmacopeia. 2023. Available from: https:\/\/go.usp.org\/USP_GC_797_FAQs. Accessed March 5 2025."}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251355333","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251355333","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251355333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:53Z","timestamp":1777509233000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251355333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/08971900251355333"],"URL":"https:\/\/doi.org\/10.1177\/08971900251355333","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}